A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Phase of Trial: Phase III
Latest Information Update: 06 Jan 2020
Price : $35 *
At a glance
- Drugs Mirikizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms OASIS-3
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 02 Oct 2018 Status changed from not yet recruiting to recruiting.
- 26 Sep 2018 Planned initiation date changed from 25 Sep 2018 to 2 Oct 2018.
- 21 Jun 2018 New trial record